October 18, 2018

Newborn Screening Update for Duchenne Muscular Dystrophy

The Duchenne muscular dystrophy (DMD) community took two big steps toward newborn screening this month. Newborn screening programs are important because they allow early diagnosis even before symptoms are observed. Newborn screening facilitates early treatment and rapid development of new therapies for infants everywhere.

When infants are born in the United States, a heel prick blood sample is taken onto a paper card. The card is tested for a set of metabolic and genetic disorders at a public health laboratory. Once a disorder has been added to the national screening panel, each state determines whether to add it to their state testing card. You can learn more about newborn screening at http://www.babysfirsttest.org/.

Two major DMD patient advocacy groups shared news about their work to support newborn screening for DMD. Parent Project Muscular Dystrophy (PPMD) and CureDuchenne are working on different ways to make newborn screening a reality for everyone.

PPMD announced the launch of their newborn screening pilot in New York State (https://www.parentprojectmd.org/ppmd-launches-duchenne-newborn-screening-pilot-in-new-york-state/). Their pilot is a collaboration between industry, New York State Department of Health, and the Centers for Disease Control. The pilot study will collect data needed to add DMD to the national and state panels. Once DMD is added to the state testing cards, then every infant will be tested for free.

CureDuchenne announced a new partnership with Baebies to develop newborn screening tests for DMD (https://www.cureduchenne.org/press-release/cureduchenne-partners-with-baebies-to-accelerate-newborn-screening-for-duchenne-muscular-dystrophy/). These tests would be ordered by a doctor and paid for by health insurance. This would provide testing for infants born before the national panel is changed, or for infants born in places that do not have DMD on the state card.

The DMD community is supported by many strong and devoted advocacy groups. Everyone is committed to supporting families, advancing research, and thinking creatively about how to help people with DMD.

October 10, 2018

World Muscle Society was a great success for TRiNDS, CINRG, and TRiNDS’ clients and collaborators. In addition to three days of presentations, researchers presented over 175 posters in a poster session. Poster presentations shared results from all different types of research and clinical trials about all different types of neuromuscular disorders. We had a great time sharing our results at the poster session and connecting with each other.

The Cooperative International Neuromuscular Research Group (CINRG) is a consortium of researchers who work together on industry sponsored and academic research projects about people with neuromuscular disorders. Everyone works hard to answer important research questions for patients and families everywhere. Congratulations CINRG researchers on your WMS presentations!

Conferences are a great opportunity for the scientific community to share results and build relationships for future projects. We always come home more energized and more committed to neuromuscular research than ever.

TRiNDS is the coordinating center for CINRG. TRiNDS serves industry and academic research clients working for neuromuscular disorders around the world. Click here to request a quote for services.


October 3, 2018

Building Your Team: Becker Muscular Dystrophy

Next week is Becker Muscular Dystrophy (BMD) Awareness Week, a time for everyone to recognize the families around the world living with BMD.

BMD affects 1 in 35,000 males worldwide. People with BMD show symptoms of muscle weakness in the teen years and can often keep walking into adulthood. Even though good outcomes are possible with BMD, it’s important to work with the medical team to maintain function and good health at diagnosis and beyond. Just like other kinds of muscular dystrophy, people with BMD can develop heart symptoms and other important changes that need management over the lifespan.

Gathering a strong medical team is the best way to get started with managing BMD. The Muscular Dystrophy Association has some great resources for providers and patients. Check out their medical management guide and get started today. (https://www.mda.org/disease/becker-muscular-dystrophy/medical-management)

TRiNDS works with academic and industry researchers on all types of neuromuscular disorders. If you’re getting ready to launch a NMD project, click here to request a quote for TRiNDS’ services.

October 2, 2018

See you at World Muscle Society!

TRiNDS and the NS Pharma team are beginning their long journeys to the World Muscle Society Congress 2018 in Mendoza, Argentina.  The conference begins today and will close on October 6th.  Are you going to the meeting?  You can meet the team during the poster session on October 3rd.
 
The World Muscle Society https://www.worldmusclesociety.org/ is a global organization of neuromuscular professionals and researchers. Each year, members travel from around the world to share updates about academic research and clinical drug development for Duchenne Muscular Dystrophy and other neuromuscular disorders. It’s an important opportunity for everyone to hear the latest work, to learn from each other, and to see where the field of neuromuscular research is going. We are excited to learn about all the great work researchers and companies are doing to test innovative new ideas.
 
TRiNDS works for academic research and industry development clients working to improve the lives of people with neuromuscular disorders.  We are proud to support our clients in their work to test new ideas for patients around the world.
 
Looking for information about a TRiNDS project? Email info@trinds.com to connect with the study team.

Newborn Screening Update for Duchenne Muscular Dystrophy

October 18, 2018

Newborn Screening Update for Duchenne Muscular Dystrophy

The Duchenne muscular dystrophy (DMD) community took two big steps toward newborn screening this month. Newborn screening programs are important because they allow early diagnosis even before symptoms are observed. Newborn screening facilitates early treatment and rapid development of new therapies for infants everywhere.

When infants are born in the United States, a heel prick blood sample is taken onto a paper card. The card is tested for a set of metabolic and genetic disorders at a public health laboratory. Once a disorder has been added to the national screening panel, each state determines whether to add it to their state testing card. You can learn more about newborn screening at http://www.babysfirsttest.org/.

Two major DMD patient advocacy groups shared news about their work to support newborn screening for DMD. Parent Project Muscular Dystrophy (PPMD) and CureDuchenne are working on different ways to make newborn screening a reality for everyone.

PPMD announced the launch of their newborn screening pilot in New York State (https://www.parentprojectmd.org/ppmd-launches-duchenne-newborn-screening-pilot-in-new-york-state/). Their pilot is a collaboration between industry, New York State Department of Health, and the Centers for Disease Control. The pilot study will collect data needed to add DMD to the national and state panels. Once DMD is added to the state testing cards, then every infant will be tested for free.

CureDuchenne announced a new partnership with Baebies to develop newborn screening tests for DMD (https://www.cureduchenne.org/press-release/cureduchenne-partners-with-baebies-to-accelerate-newborn-screening-for-duchenne-muscular-dystrophy/). These tests would be ordered by a doctor and paid for by health insurance. This would provide testing for infants born before the national panel is changed, or for infants born in places that do not have DMD on the state card.

The DMD community is supported by many strong and devoted advocacy groups. Everyone is committed to supporting families, advancing research, and thinking creatively about how to help people with DMD.

News

Success at WMS

October 10, 2018

World Muscle Society was a great success for TRiNDS, CINRG, and TRiNDS’ clients and collaborators. In addition to three days of presentations, researchers presented over 175 posters in a poster session. Poster presentations shared results from all different types of research and clinical trials about all different types of neuromuscular disorders. We had a great time sharing our results at the poster session and connecting with each other.

The Cooperative International Neuromuscular Research Group (CINRG) is a consortium of researchers who work together on industry sponsored and academic research projects about people with neuromuscular disorders. Everyone works hard to answer important research questions for patients and families everywhere. Congratulations CINRG researchers on your WMS presentations!

Conferences are a great opportunity for the scientific community to share results and build relationships for future projects. We always come home more energized and more committed to neuromuscular research than ever.

TRiNDS is the coordinating center for CINRG. TRiNDS serves industry and academic research clients working for neuromuscular disorders around the world.

Click here to request a quote for services.

Building Your Team: Becker Muscular Dystrophy

October 3, 2018

Building Your Team: Becker Muscular Dystrophy

Next week is Becker Muscular Dystrophy (BMD) Awareness Week, a time for everyone to recognize the families around the world living with BMD.

BMD affects 1 in 35,000 males worldwide. People with BMD show symptoms of muscle weakness in the teen years and can often keep walking into adulthood. Even though good outcomes are possible with BMD, it’s important to work with the medical team to maintain function and good health at diagnosis and beyond. Just like other kinds of muscular dystrophy, people with BMD can develop heart symptoms and other important changes that need management over the lifespan.

Gathering a strong medical team is the best way to get started with managing BMD. The Muscular Dystrophy Association has some great resources for providers and patients. Check out their medical management guide and get started today. (https://www.mda.org/disease/becker-muscular-dystrophy/medical-management)

TRiNDS works with academic and industry researchers on all types of neuromuscular disorders. If you’re getting ready to launch a NMD project, click here to request a quote for TRiNDS’ services.

WMS

October 2, 2018

See you at World Muscle Society!

TRiNDS and the NS Pharma team are beginning their long journeys to the World Muscle Society Congress 2018 in Mendoza, Argentina.  The conference begins today and will close on October 6th.  Are you going to the meeting?  You can meet the team during the poster session on October 3rd.

 

The World Muscle Society https://www.worldmusclesociety.org/ is a global organization of neuromuscular professionals and researchers. Each year, members travel from around the world to share updates about academic research and clinical drug development for Duchenne Muscular Dystrophy and other neuromuscular disorders. It’s an important opportunity for everyone to hear the latest work, to learn from each other, and to see where the field of neuromuscular research is going. We are excited to learn about all the great work researchers and companies are doing to test innovative new ideas.

 

TRiNDS works for academic research and industry development clients working to improve the lives of people with neuromuscular disorders.  We are proud to support our clients in their work to test new ideas for patients around the world.

 

Looking for information about a TRiNDS project? Email info@trinds.com to connect with the study team.